2017

Declining Risk of Sudden Death in Heart Failure
 

Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Zannad F, Pfeffer MA, Bhatt DL, Bonds DE, Borer JS, Calvo-Rojas G, Fiore L, Lund LH, Madigan D, Maggioni AP, Meyers CM, Rosenberg Y, Simon T, Stough WG, Zalewski A, Zariffa N, Temple R. Heart. 2017 Apr 28

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F. Eur Heart J. 2017 Apr 18

 

2016 

Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Rossignol P, Legrand M, Kosiborod M, Hollenberg SM, Peacock WF, Emmett M, Epstein M, Kovesdy CP, Yilmaz MB, Stough WG, Gayat E, Pitt B, Zannad F, Mebazaa A.

Pharmacol Res. 2016 Nov;113(Pt A):585-591

 

New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.

Zannad F, Rossignol P, Stough WG, Epstein M, Alonso Garcia Mde L, Bakris GL, Butler J, Kosiborod M, Berman L, Mebazaa A, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B.

Int J Cardiol. 2016 Aug 1;216:46-51. doi: 10.1016/j.ijcard.2016.04.127. Epub 2016 Apr 19.

 

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion

Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso García Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G.

Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):200-5

 

Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.

Mentz RJ, Roessig L, Greenberg BH, Sato N, Shinagawa K, Yeo D, Kwok BW, Reyes EB, Krum H, Pieske B, Greene SJ, Ambrosy AP, Kelly JP, Zannad F, Pitt B, Lam CS.

JACC Heart Fail. 2016 Jun;4(6):419-27

 

Neural modulation for hypertension and heart failure.

Smith S, Rossignol P, Willis S, Zannad F, Mentz R, Pocock S, Bisognano J, Nadim Y, Geller N, Ruble S, Linde C.Int J Cardiol. 2016 Jul 1;214:320-30.

 

2015 

Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction

Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC, Holzmeister J, Lam CS, Pochet T, Vincent A, Linde C Eur J Heart Fail. 2015 Feb;17(2):135-43. doi: 10.1002/ejhf.208. Epub 2014 Dec 3. .

 

Patient selection in heart failure with preserved ejection fraction clinical trials

Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, O'Connor CM, Lam CS J Am Coll Cardiol. 2015 Apr 28;65(16):1668-82. doi: 10.1016/j.jacc.2015.03.043.

 

Atherosclerosis: Recent trials, new targets and future directions

Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W Int J Cardiol. 2015 Aug 1;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 8. Review. 

 

Agents with vasodilator properties in acute heart failure: how to design successful trials

Mebazaa A, Longrois D, Metra M, Mueller C, Richards AM, Roessig L, Seronde MF, Sato N, Stockbridge N, Gattis Stough W, Alonso A, Cody R, Cook Bruns N, Gheorghiade M, Holzmeister J, Laribi S, Zannad F European Journal of Heart Failure (2015) 17, 652–664 doi:10.1002/ejhf.294. Review .

 

Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction.

Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC, Holzmeister J, Lam CS, Pochet T, Vincent A, Linde C. 
Eur J Heart Fail. 2015 Feb;17(2):135-43. doi: 10.1002/ejhf.208. Epub 2014 Dec 3.
 

Patient selection in heart failure with preserved ejection fraction clinical trials.

Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, O'Connor CM, Lam CS.
J Am Coll Cardiol. 2015 Apr 28;65(16):1668-82. doi: 10.1016/j.jacc.2015.03.043.
 

Atherosclerosis: Recent trials, new targets and future directions.

Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W.
Int J Cardiol. 2015 Aug 1;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 8. Review.
 

Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure.

Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Piña IL, Stein K, Azizi M. Hypertension. 2015 Jan;65(1):5-15

 

2014

Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.

Rossignol P, Zannad F, Pitt B; Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France.. Int J Cardiol. 2014 Dec 20;177(3):731-3

 

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM J Am Coll Cardiol. 2014 Dec 2;64(21):2281-93. doi: 10.1016/j.jacc.2014.08.036. Epub 2014 Nov 24. Review. 

 

Current challenges for clinical trials of cardiovascular medical devices.
Zannad F, Stough WG, Piña IL, Mehran R, Abraham WT, Anker SD, De Ferrari GM, Farb A, Geller NL, Kieval RS, Linde C, Redberg RF, Stein K, Vincent A, Woehrle H, Pocock SJ. Int J Cardiol. 2014 Jul 15;175(1):30-7.
http://dx.doi.org/10.1016/j.ijcard.2014.05.021

 

Trials of implantable monitoring devices in heart failure: which design is optimal?
Abraham WT, Stough WG, Piña IL, Linde C, Borer JS, De Ferrari GM, Mehran R, Stein KM, Vincent A, Yadav JS, Anker SD, Zannad F. Nat Rev Cardiol. 2014 Oct;11(10):576-85.

Nature Reviews Cardiology 2014 doi:10.1038/nrcardio.2014.114

 

Charting a Roadmap for Heart Failure Biomarker Studies
Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, Snider JV, Blankenberg S, Adams KF, Redberg RF, Kim JB, Mascette A, Mentz RJ, O’Connor CM, Felker GM, Januzzi JL. JACC Heart Fail. 2014 Oct;2(5):477-488.

 

Decongestion in acute heart failure. 
Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, Gheorghiade M, Fiuzat M, Rossignol P, Zannad F, Pitt B, O’Connor C, Felker GM. Eur J Heart Fail. 2014 May;16(5):471-82.

 

Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties.

Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, Cohen-Solal A, Gheorghiade M, Gueyffier F, O’Connor CM, Fiuzat M, Patak A, Piña IL, Rosano G, Sabbah HN, Tavazzi L, Zannad F. Eur J Heart Fail. 2014 Jan;16(1):76-85.

 

2013

Learning from recent trials and shaping the future of acute heart failure trials. 
Mentz RJ, Felker GM, Ahmad T, Peacock WF, Pitt B, Fiuzat M, Maggioni AP, Gheorghiade M, Ando Y, Pocock SJ, Zannad F, O’Connor CM. Am Heart J. 2013 Oct;166(4):629-35.

 

Biomarker-guided therapies in heart failure: a forum for unified strategies.

Fiuzat M, O’Connor CM, Gueyffier F, Mascette AM, Geller NL, Mebazaa A, Voors AA, Adams KF, Piña IL, Neyses L, Muntendam P, Felker GM, Pitt B, Zannad F, Bristow MR. J Card Fail. 2013 Aug;19(8):592-9.

 

The past, present and future of renin-angiotensin aldosterone system inhibition.

Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, O’Connor CM, Zannad F, Pitt B. Int J Cardiol. 2013 Sep 1;167(5):1677-87.

 

2012

Implications of geographical variation on clinical outcomes of cardiovascular trials.

Mentz RJ, Kaski JC, Dan GA, Goldstein S, Stockbridge N, Alonso-Garcia A, Ruilope LM, Martinez FA, Zannad F, Pitt B, Fiuzat M, O’Connor CM. Am Heart J. 2012 Sep;164(3):303-12.

 

2008

Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. European Heart Journal 2007;28:1904-1909.

Borer JS1, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, Pitt B, Zannad F. Eur Heart J. 2007 Aug;28(15):1904-9.

Globalization of cardiovascularclinical research: the balance between meeting medical needs and maintaining scientific standards. American Heart Journal 2007;154:232-8

Stough WG1, Zannad F, Pitt B, Goldstein S. Am Heart J. 2007 Aug;154(2):232-8.

Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J 2008;29:413-21.

Zannad F, Stough WG, Pitt B, Cleland JG, Adams KF, Geller NL, Torp-Pedersen C, Kirwan BA, Follath F. Eur Heart J. 2008 Feb;29(3):413-21.

Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials. Cardiology 2008;110:73-80

Lewis RM, Gordon DJ, Poole-Wilson PA, Borer JS, Zannad F. Cardiology. 2008;110(2):73-80..